Manuscripts

TITLE Journal Authors DOI
Effectiveness of Ledipasvir-sofosbuvir Combination in Patients with Hepatitis C Virus Infection and Factors Associated of Sustained Virologic Response Gastro-enterology Norah Terrault, Stefan Zeuzem, Adrian M Di Bisceglie, Joseph K Lim, Paul J Pockros, Lynn M Frazier, Alexander Kuo, Anna S Lok, Mitchell L Shiffman, Ziv Ben Ari, Lucy Akushevich, Monika Vainorius, Mark S Sulkowski, Michael W Fried, David R Nelson PMID: 27565882
DOI: 10.1053/j.gastro.2016.08.004
Effectiveness and safety of sofosbuvir-based regimens for the treatment of chronic hepatitis C virus genotype 3 infection: results of the HCV-TARGET study (G3) CID Feld, Mann, Zeuzem, Kuo, Nelson, Di Bisceglie, Manns, Sherman, Frazier, Sterling, Mailliard. PMID: 27325691 PMCID: PMC4996139 [Available on 2017-09-15]
DOI: 10.1093/cid/ciw387
Sofosbuvir plus Ribavirin for the Treatment of HCV Genotype 2 Infection: Results of the Real-World, Clinical Practice HCV-TARGET Study (G2) GUT Tania M. Welzel1, David R. Nelson2, Giuseppe Morelli; Adrian Di Bisceglie; Raj Reddy; Alexander Kuo; Joseph K. Lim; Jama Darling; Paul Pockros; Joseph Galati; Lynn M. Frazier; Saleh Alqahtani; Mark S. Sulkowski; Monika Vainorius, Lucy Akushevich, Michael W. Fried; Stefan Zeuzem1 PMID: 27418632
DOI: 10.1136/gutjnl-2016-311609
Safety and Efficacy of Sofosbuvir-Containing Regimens in Hepatitis C Infected Patients with Reduced Renal Function Liver International Varun Saxena1; Farrukh M. Koraishy2, Meghan Sise3, Joseph K. Lim4, Monica Schmidt5, Raymond T. Chung3, Annmarie Liapakis4, David R. Nelson6, Michael W. Fried5, Norah Terrault1 and HCV-TARGET PMID: 26923436
DOI: 10.1111/liv.13102
Interferon-free Therapy for Genotype 1 Hepatitis C in Liver Transplant Recipients: Real World Experience from HCV-TARGET Liver Transplantation Robert S. Brown, Jr., M.D., M.P.H1., Jacqueline G. O’Leary M.D2, K. Rajender Reddy M.D3, Alexander Kuo4, Giuseppe Morelli5, R. Todd Stravitz6, Christine Durand7, Adrian M. Di Bisceglie8, Hugo E. Vargas9, Paul Kwo10, Catherine T. Frenette11, Thomas G. Stewart12, David R. Nelson5, Michael W. Fried12, and Norah Terrault  M.D13 on behalf of HCV-TARGET Study Group PMID: 26519873
DOI: 10.1002/lt.24366
Effectiveness of Simeprevir plus Sofosbuvir with or without ribavirin for the treatment of patients with HCV genotype 1 infection in real-world clinical practice:  The HCV TARGET Study Gastro-enterology Sulkowski MS1, Vargas HE, Di Bisceglie AM, Kuo, PA, Reddy KR, Lim JK, Morelli G,  Darling JM, Feld JJ,  Brown RS, Frazier LM, Stewart TG, Fried MW,  Nelson DR, and Jacobson IM for the HCV-TARGET Study Group PMID: 26497081 PMCID: PMC4727992 [Available on 2017-02-01]
DOI: 10.1053/j.gastro.2015.10.013
VIROLOGIC OUTCOMES AND ADHERENCE TO TREATMENT ALGORITHMS IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH BOCEPREVIR OR TELAPREVIR Alimentary Pharmacology and Therapeutics AP & T Richard K. Sterling,1 Alexander Kuo,2 Vinod K Rustgi,3 Mark S. Sulkowski,4 Thomas G. Stewart,5 Jonathan M. Fenkel,6 Hisham El-Genaidi,7 Mitchell A. Mah’moud,8 George M. Abraham,9 Paul Stewart, David R. Nelson, Michael W. Fried,5 Adrian M. Di Bisceglie10 for the HCV-TARGET Study Group  doi:10.1111/apt.13095
Adverse Events With Boceprevir or Telaprevir in Chronic Hepatitis C: Real-World Experience From HCV-TARGET. Journal of Hepatology Stuart C. Gordon, MD,1* Andrew J. Muir, MD, MHS,2 Joseph K. Lim, MD,3 Brian Pearlman, MD,4 Curtis K. Argo, MD,5 Ananthakrishnan Ramani, MD,6 Benedict Maliakkal, MD,7 Imtiaz Alam,8 Thomas G. Stewart, MD,9 Monika Vainorius, MD,9 Joy Peter, RN,10 David R. Nelson, MD,10 Michael W. Fried, MD,9 K. Rajender Reddy, MD,11* for the HCV-TARGET Study Group http://dx.doi.org/10.1016/j.jhep.2014.08.052
Successful therapy of Hepatitis C with daclatasvir, pegylated interferon and ribavirin after failure with boceprevir based therapy in a liver transplant recipient with hyper-IgM syndrome Transplantation K.Rajender Reddy, Amina Wirjosemito, Lorie Sinese, Eric Hughes, Patricia Mendez 10.1097/TP.0000000000000076

Oral Presentations

TITLE Authors
HCV-TARGET, The Hepatitis C Therapeutic Registry and Research Network For Novel Clinical and Translational Studies DR Nelson, JA Peter, DM Jensen, AM DiBisceglie, MS Sulkowski, N Terrault and MW Fried for HCV-TARGET
HCV-TARGET: A Longitudinal, Observational Study of North American Patients with Chronic Hepatitis C (HCV) Treated with Boceprevir or Telaprevir Nelson DR, Reddy KR, Di Bisceglie AM, Jensen DM, Jacobson IM, Sulkowski M, Terrault N, Afdhal NA, Gordon S, Pockros P, Kwo P, Everson G, Sherman KE, Muir AJ, Pearlman B, Stewart TG, Vainorius M, Peter JA, and Fried MW for the HCV-TARGET Study Group
VIROLOGIC OUTCOMES AND ADHERENCE TO TREATMENT ALGORITHMS IN A LONGITUDINAL STUDY OF PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH BOCEPREVIR OR TELAPREVIR IN THE UNITED STATES (HCV-TARGET). AM Di Bisceglie, A Kuo, VK Rustgi, MS Sulkowski, TG Stewart, JM Fenkel, H ElGenaidi, M Mah’moud, GM Abraham, MW Fried, RK Sterling for the HCV-TARGET Study Group
Impact of Age on Safety and Treatment Response in Patients with Hepatitis C (HCV) Treated With Boceprevir or Telaprevir A Aronsohn, T Stainbrook, S Mohanty, A Mubarak, J Spivey, P Prashant, T Stewart, MW Fried, I Jacobson or the HCV-TARGET Study Group
Safety and Efficacy of Sofosbuvir-Containing Regimens for Hepatitis C: Real-World Experience in a Diverse, Longitudinal Observational Cohort Donald M. Jensen1, Jacqueline G. O’Leary2, Paul J. Pockros3, Kenneth E. Sherman4, Paul Y. Kwo5, Mark E. Mailliard6, Kris V. Kowdley7, Andrew J. Muir8, Rolland C. Dickson9, Ananthakrishnan Ramani10, Michael P. Manns 11, Anna S. Lok12, Lucy Akuskevich13, David R. Nelson14, Michael W. Fried13
Safety and Efficacy of New DAA-based Therapy for Hepatitis C Post-Transplant: Interval Results from the HCV-TARGET Longitudinal, Observational Study Robert S. Brown, K. Rajender Reddy, Jacqueline G. O’Leary, Alexander Kuo, Giuseppe Morelli, R. Todd Stravitz, Christine Durand, Adrian M. Di Bisceglie, Hugo E. Vargas, Paul Kwo, Catherine T. Frenette, Monika Vainorius, Lucy Akushevich, Michael W. Fried, Norah Terrault
All Oral HCV Therapy is Safe and Effective in Patients with Decompensated Cirrhosis: Interim Report From the HCV-TARGET Real World Experience K. Rajender Reddy, Joseph K. Lim, Alexander Kuo, Adrian M. Di Bisceglie, Hugo E. Vargas, Joseph S. Galati, Giuseppe Morelli, Gregory T. Everson, Paul Kwo, Robert Brown, Mark S. Sulkowski, Lucy Akushevich, Thomas G. Stewart, Monika Vainorius, Joy A. Peter, David R. Nelson, Michael W. Fried, Michael P. Manns* for the HCV-TARGET Study Group
Safety and Efficacy of All Oral DAA Therapy for Genotype 1 HCV Post-Liver Transplant: Interval Results from the HCV-TARGET Multicenter Prospective Observational Study Jacqueline G. O’Leary, Robert S. Brown, K. Rajender Reddy, Alexander Kuo, Giuseppe Morelli, R. Todd Stravitz, Gregory T. Everson, Christine M. Durand, Adrian M. Di Bisceglie, Hugo E. Vargas, Paul Kwo, Catherine T. Frenette, Joy A. Peter, Monika Vainorius, Lucy Akushevich, David R. Nelson, Michael W. Fried, Norah Terrault
SAFETY AND EFFICACY OF LEDIPASVIR/SOFOSBUVIR FOR THE TREATMENT OF HEPATITIS C INFECTION: INTERIM ANALYSIS OF A PROSPECTIVE, OBSERVATIONAL STUDY Nelson D, Zeuzem S , Terrault N, Pockros P, Lim JK, Kuo A, Lok AS, Manns M,  Elbeshbeshy H, Frazier L, Stewart P, Sulkowski M, Fried MW
Treatment Outcomes With 8, 12 and 24 Week Regimens of Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Infection: Analysis of a Multicenter Prospective, Observational Study Terrault N, Zeuzem S, Di Bisceglie AM, Lim JK , Pockros P, Frazier L, Kuo A, Lok AS, Shiffman M, Ben-Ari Z, Stewart T, Sulkowski M, Fried MW, Nelson DR.
SAFETY AND EFFICACY OF ORAL REGIMENS FOR THE TREATMENT OF HEPATITIS C GENOTYPE 1b INFECTION: HCV-TARGET INTERIM ANALYSIS OF A PROSPECTIVE, OBSERVATIONAL STUDY.  Lead Author- Michael Manns. Manns M, Nelson DR, Zeuzem S , Di Bisceglie AM, Ben-Ari, Z, Lok AS, Pockros P, Lim JK, Kuo A, Reddy R, Frazier L, Stewart P, Vainorius M, Sulkowski MS, Fried M
PREVALENCE AND IMPACT OF BASELINE RESISTANCE-ASSOCIATED VARIANTS (RAVS) ON THE EFFICACY OF LEDIPASVIR/SOFOSBUVIR OR SIMEPREVIR/SOFOSBUVIR AGAINST GT1 HCV INFECTION: HCV-TARGET INTERIM ANALYSIS Gary P. Wang* 1, 2, Jackie D. Reeves3, Norah Terrault4, Joseph K. Lim5, Giuseppe Morelli1, Alexander Kuo6, Josh Levitsky7, Kenneth Sherman8, Lynn M. Frazier9, Ananthakrishnan Ramani10, Joy Peter1, Lucy Akuskevich11, Michael W. Fried11, David R. Nelson1

Posters

TITLE Authors
HCV-TARGET: A Longitudinal, Observational Study of North American Patients with Chronic Hepatitis C (HCV) Treated with Boceprevir or Telaprevir Fried MW, Reddy KR, Di Bisceglie AM, Jensen DM, Jacobson IM, Sulkowski M, Terrault N, Afdhal NA, Gordon S, Pockros P, Kwo P, Everson G, Sherman KE, Muir AJ, Pearlman B, Stewart TG, Vainorius M, Peter JA, and Nelson DR for the HCV-TARGET Study Group
Safety and Efficacy of Telaprevir (TVR) or Boceprevir (BOC) in Patients with Cirrhosis: Interim Results of a Longitudinal, Observational Study Afdhal NH, Reau N, Everson GT, Morelli G, Lok AS, Sherman KE, Dickson RC, Regenstein F, Mean EA, Stewart TG,  Fried MW,  Pockros P for the HCV-TARGET Study Group
The Frequency and Management of Adverse Events in Chronic Hepatitis C (HCV) Treated with Boceprevir or Telaprevir: Real World Experience from the HCV-TARGET Longitudinal Observational Study Gordon SC, Muir AJ, Lim JK, Pearlman BL, Argo CK, Neff GW, Ramani A, Maliakkal B, Rodriguez-Torres M, Stewart TG, Fried MW, Reddy KR for the HCV-Target Study Group
Pre-Treatment Education and Treatment Completion in Patients with Hepatitis C (HCV) Treated with Boceprevir (BOC) or Telaprevir (TVR) Mercier DA, Appolo BA, Cardona D, Stewart TG, Vainorius M, Scherschel A, Horne P, Hubbard SB, Keller AL, Richards L, Peter J, for the HCV-TARGET Study Group
HCV Treatment Selection and Duration Decision-Making: Real-World Issues with HCV RNA and HCV Genotype Assays Used in Clinical Practice. MW Fried1, M Vainorius1, KR Reddy2, AM Di Bisceglie3, DM Jensen4, IM Jacobson5, M Sulkowski6, N Terrault7, K Bergquist1, TG Stewart1, JA Peter8, and DR Nelson8 for the HCV-TARGET Study Group
Safety and Efficacy of Sofosbuvir (SOF) in Combination with Simeprevir (SIM) + Ribavirin (RBV) in Patients with Genotype 1: Interim Results of a Prospective, Observational Study Mark S. Sulkowski1, Hugo E. Vargas2, Adrian M. Di Bisceglie3, Alexander Kuo4, K. Rajender Reddy5, Joseph K. Lim6, Giuseppe Morelli7, Jordan J. Feld 12, Robert S. Brown8, Lynn M. Frazier9, Michael W. Fried10, David R. Nelson7, Ira M. Jacobson11
SAFETY AND EFFECTIVENESS OF SOFOSBUVIR-BASED REGIMENS FOR THE TREATMENT OF HEPATITIS C GENOTYPE 3 AND 4 INFECTIONS: INTERIM ANALYSIS OF A PROSPECTIVE, OBSERVATIONAL STUDY Saleh Alqahtani* 1 , Stefan Zeuzem 2 , Michael Manns3 , Alexander Kuo4 , Adrian M. Di Bisceglie5 , Rajender Reddy6 , Mark Mailliard7 , Jaqueline O’Leary8 , Paul Pockros9 , Paul Y. Kwo10 , Joseph K. Lim11, Hugo E. Vargas12 , Michael W. Fried13 , David Nelson14 , Mark S. Sulkowski1
Safety and Efficacy of Sofosbuvir-Containing Regimens in Hepatitis C Infected Patients with Reduced Renal Function: Real-World Experience from HCV-TARGET Varun Saxena1, Farrukh M. Koraishy2, Meghan Sise3, Joseph K. Lim4, Raymond T. Chung3, Annmarie Liapakis4, David R. Nelson5, Monica Schmidt6, Michael W. Fried6, Norah Terrault1 and HCV-TARGET
Safety and Efficacy of Sofosbuvir and Ribavirin for the Treatment of HCV Genotype 2 and 3: Results of the HCV-TARGET Study Tania M. Welzel, David R. Nelson, Giuseppe Morelli; Adrian Di Bisceglie; Raj Reddy; Alexander Kuo; Joseph K. Lim; Jama Darling; Paul Pockros; Joseph Galati; Lynn M. Frazier; Saleh Alqahtani; Mark S. Sulkowski; Michael W. Fried; Stefan Zeuzem
SAFETY AND EFFICACY OF NEW DAA REGIMENS IN KIDNEY AND LIVER TRANSPLANT RECIPIENTS WITH HEPATITIS C: INTERVAL RESULTS FROM THE HCV-TARGET STUDY K. R. Reddy* 1, Mark S. Sulkowski2, Mohamed Hassan3, Josh Levitsky4, Jacqueline O’Leary5, Robert S. Brown6, Elizabeth C. Verna6, Alexander Kuo7, R. T. Stravitz8, Joseph K. Lim9, Varun Saxena10, David R. Nelson11, Paul Hayashi12, Monika Vainorius12, Michael W. Fried12, Norah Terrault10
Safety and Tolerability of Direct Acting Antiviral Agents (DAAs) Used in Usual Clinical Practice: HCV-TARGET International Consortium Michael Fried, Rajender Reddy, Mitchell Shiffman, Stefan Zeuzem, Norah Terrault, Alexander Kuo, Paul Pockros, Mark Sulkwoski, Michael Manns, Jacqueline O’Leary, Luck Akushevich, Monika Vainorius, David Nelson, Joseph Lim
SAFETY AND EFFECTIVENESS OF 12 AND 24-WEEK REGIMENS OF PARITAPREVIR/R, OMBITASVIR, DASABUVIR (PrOD) FOR THE TREATMENT OF HEPATITIS C GENOTYPE 1A INFECTION: INTERIM ANALYSIS HCV-TARGET, A PROSPECTIVE, OBSERVATIONAL STUDY Shiffman, ML, Lim, JK; Lok, AS; Zeuzem, S; Terrault, N; Park, JS; Landis, C; Hassan, M; Gallant, J; Kuo, A; Pockros, P; Vainorius, M; Akushevich, L; Fried MW; Nelson, DR; Ben-Ari, Z
SAFETY AND EFFECTIVENESS OF 12 AND 24-WEEK REGIMENS OF LEDIPASVIR/SOFOSBUVIR (LDV/SOF) IN TREATMENT EXPERIENCED GENOTYPE 1 CIRRHOSIS: INTERIM ANALYSIS HCV-TARGET, A PROSPECTIVE, OBSERVATIONAL STUDY Shiffman, ML, Lim, JK; Lok, AS; Zeuzem, S; Terrault, N; Park, JS; Landis, C; Hassan, M; Gallant, J; Kuo, A; Pockros, P; Vainorius, M; Akushevich, L; Fried MW; Nelson, DR; Ben-Ari, Z